Retatrutide

Description

Retatrutide (LY3437943) is an investigational triple-agonist peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors. Developed by Eli Lilly, it is designed to enhance metabolic regulation, reduce appetite, increase energy expenditure, and improve glucose control. Early clinical studies show unprecedented levels of weight reduction, making retatrutide one of the most promising next-generation metabolic therapeutics. It is currently being evaluated for obesity, type 2 diabetes, and metabolic disorders.

Research-Only Use:
This material is not intended for human consumption, clinical use, or veterinary applications. No claims are made regarding safety or efficacy for in vivo purposes or applications.

Disclaimer:
The information presented here is not intended to diagnose, treat, cure, or prevent any disease; it is provided for scientific and research purposes only. Statements have not been evaluated by any regulatory authority. Product use is restricted to qualified researchers or institutions in accordance with all applicable UK laws and regulations.

Terms of Sale:
By purchasing this item, you confirm that you are a qualified researcher, institution, or laboratory operating within legally-permitted research guidelines. We shall not be held liable for any loss, injury, claim, or damage resulting from misuse, improper handling, unauthorized application, or illegal distribution of any item purchased.